LETTERS TO THE EDITOR

Prevention of intraventricular haemorrhage in preterm infants in Britain and Ireland

EDITOR,—Intraventricular or periventricular haemorrhage is a potential cause of morbidity and mortality in preterm infants. Many potential treatments have been studied but three in particular have influenced practice in the British Isles: vitamin E¹; ethamsylate²; and fresh frozen plasma.³

Meta-analysis has shown no consistent benefit for any postnatal preventive treatment.⁴ We were aware that the use of prophylaxis against intraventricular haemorrhage varied in different units and we wished to gain a picture of the pattern of prophylaxis use throughout Britain and Ireland.

A short postal questionnaire was sent to each neonatal unit asking whether prophylaxis was used and what criteria were used

Type of prophylaxis used	Number of neonatal units	Percentage total replies (n=254)
Vitamin E	46	18.1
Ethamsylate	53	20.9
Fresh frozen plasma	33	13
Other*	3	1.2

*Of those units using other than ethamsylate, vitamin E, or fresh frozen plasma, two units used routine volume expansion with human albumin solution and one unit is using routine phenobarbitone.

to decide on the requirement for prophylaxis. Statistical analysis was done using χ^2 analysis.

Ninety nine point two per cent of units responded, giving a total of 254 replies. Ninety four (37%) units use a prophylactic treatment for the prevention of intraventricular haemorrhage in preterm infants (table). Sixteen point two per cent of neonatal units are using more than one type of prophylaxis.

Eighty five point one per cent of the 94 units using prophylaxis used a gestational age criterion, most often less than or equal to 32 weeks of completed gestation; 69.1% of units used a birthweight criterion, most often less than or equal to 1500 g birth weight. Eight point five per cent of units used other criteria, such as the ventilatory requirement of the baby; 62% use a combination of birthweight and gestational age criteria.

There was no significant difference in prophylaxis use between regional subregional or district general hospitals. There was, however, a noticeable difference between different geographical areas of the country. Vitamin E was used much more often in the west of England and in Scotland. Routine volume expansion with fresh frozen plasma was most often used in the east of England. Ethamsylate was most often used in the west of England and in Wales (figure).

Our survey clearly shows that most neonatal units in the United Kingdom and Ireland remain unconvinced of the effectiveness of some or all of these treatments. Notably there is no difference in prophylaxis use between hospitals with neonatal intensive care units of different sizes; this observation

* $p < 0.05$; significant difference within type of prophylaxis between areas.

Regional variations in prophylaxis use.

was of particular interest in view of the recent trend for more preterm infants to be managed in smaller units. Our results seem to show that the single factor most likely to influence the use of prophylaxis for intraventricular haemorrhage is the geographical area of the British Isles into which the baby is born. There are many possible reasons for this, but we note that the areas of highest use of a particular treatment correspond to those areas in which the trials of the respective treatments were carried out.¹⁻³ Either two thirds of babies at risk of intraventricular haemorrhage in Britain and Ireland are not getting a potentially life saving treatment or one third of at risk infants are getting unnecessary, expensive, and potentially harmful interventions. Clearly, further work is required to provide the evidence that is needed for a consensus to be achieved in this area of neonatal medicine.

I M R WRIGHT

Department of Paediatrics & Child Health,
Leeds General Infirmary,
Leeds LS2 9NS

- 1 Sinha S, Davies J, Toner N, Chiswick ML, *et al.* Vitamin E supplementation reduces frequency of periventricular haemorrhage in very preterm babies. *Lancet* 1987; i: 466-70.
- 2 Benson JWT, Drayton MR, Hayward C, Cooke RWI, *et al.* Multicentre trial of ethamsylate for prevention of periventricular haemorrhage in very low birthweight babies. *Lancet* 1986; ii: 1297-3000.
- 3 Beverley DW, Pitts-Tucker TJ, Congdon PJ, *et al.* Prevention of intraventricular haemorrhage by fresh frozen plasma. *Arch Dis Child* 1985; 60: 710-3.
- 4 Horbar JD. Prevention of periventricular-intraventricular hemorrhage. In Sinclair JC, Bracken MB, eds. *Effective care of the newborn*. Oxford: Oxford University press, 1992: 562-83.

Clinical trials and neonatal intensive care

EDITOR,—Neena Modi raises important questions about methods of obtaining assent from parents for the participation of their sick child in a clinical trial, and rightly points out that these methods deserve further scrutiny.¹

There is a dearth of empirical evidence about how parents actually feel in such circumstances. Usually, clinicians or researchers have to make assumptions about this. In a number of randomised controlled trials with which we have been involved, members of parents' groups and other voluntary organisations involved in maternity care have worked with us on the trial protocols and written information for parents. There are very few examples, however, in which the parents concerned have actually been asked for their views.^{2,3}

The Wellcome Trust has recently granted us funds for a one year project to begin to investigate this further. Part of this work will include a case study within the United Kingdom Collaborative Neonatal ECMO Trial.⁴ A working group consisting of members of relevant voluntary organisations has collaborated closely in the design of this trial. An early meeting of this group discussed the possibility of post randomisation consent for the experimental arm of the trial using a Zelen design,⁵ as advocated by Dr Modi. Although this was felt to have major advantages, the weight of opinion came down against this approach. There was concern that parents might become distressed and angry to learn that their child had been randomised to a particular treatment option without their prior knowledge. It is also scientifically worrying if, in a trial which depends crucially on continued contact with these parents, more parents in one arm of the trial than another might opt in or out. Hence the trial uses pre-randomisation consent procedures, and parents who participate are being asked for their views about this and other aspects of the trial.

Equally there is little empirical work about the views of clinicians who are participating in trials.⁶ As well as asking for the views of the parents, therefore, the study will also explore methods for ascertaining the views of such clinicians in this and other trials.

The overall aim of the study is to explore ways in which the process of participation in trials can be made less stressful. This is important both in itself and as a means of increasing recruitment to such trials. This would in turn lead to earlier and more generalisable answers about treatment options.

If readers wish to help in this exercise, we would be very interested to hear from you. Any replies of a personal nature will be treated in confidence.

DIANA ELBOURNE
JO GARCIA
CLAIRE SNOWDON
National Perinatal Epidemiology Unit,
Radcliffe Infirmary,
Oxford OX2 6HE

- 1 Modi N. Clinical trials and neonatal intensive care. *Arch Dis Child* 1994; 70: F231-2.
- 2 Matteson ME, Curb JD, McArdle R, *et al.* Participation in a clinical trial: the patients' point of view. *Controlled Clinical Trials* 1985; 6: 156-67.
- 3 Elbourne D. Subjects' views about participation in a randomized controlled trial. *J Reprod Infant Psychol* 1987; 5: 3-8.
- 4 Elbourne D. The UK Collaborative ECMO Trial. *Midwives Chronicle and Nursing Notes* 1994; 312-6.
- 5 Zelen M. A new design for randomized controlled trials. *N Engl J Med* 1979; 300: 1242-5.
- 6 Garcia J. Sharing research results with patients: the views of care-givers involved in a randomized controlled trial. *J Reprod Infant Psychol* 1987; 5: 9-13.

Audit of neonatal intensive care transport

EDITOR,—Two articles concerning transport of the critically ill neonate and child appear in the July issue of the journal.^{1,2} Seventy five per cent of 56 children transported had adverse clinical events.² This is an extremely high rate. A report of complications during transport of 614 patients in North Carolina reported complications in the neonate of 3.1% and 1.5% in paediatric patients less than 1 year old. Beyond 1 year no

complications were observed.³ I agree strongly with the authors² that inadequate stabilisation before transportation is the principal cause of complications during transfer. We have documented the time taken for stabilisation in 2863 neonatal and paediatric patients.⁴ The median stabilisation time for a neonate was 80 minutes and for a paediatric patient was 45 minutes. The time for stabilisation of a neonate reported by the Nottingham group¹ of 75 minutes is comparable with our experience.⁴ This is time very well spent. Unfortunately, a common but deplorable approach to transport reflecting an attitude of 'get that patient out of here' is very common and detrimental to patient safety during transport. This attitude of so called 'swoop and scoop' with inadequate time spent on stabilisation is rarely if ever appropriate in interfacility transfer of sick patients. There are those who claim 75–80 minutes spent stabilising a sick newborn before transfer is unnecessary – the so called (and cynical) 'stay and play' philosophy. I disagree with this. Rather stay and play and be assured a thorough stabilisation than swoop and scoop with serious but avoidable problems during the transfer.

An in-depth, very practical, and helpful revision of the 1986 American Academy of Pediatrics guidelines for air and ground transportation of paediatric patients has been recently published⁵ and is highly recommended for all facilities engaging in paediatric and neonatal transport.

JONATHAN M WHITFIELD
Baylor College of Medicine,
1 Baylor Plaza,
Houston,
Texas 77030,
USA

- 1 Leslie AJ, Stephenson TJ. Audit of neonatal intensive care transport. *Arch Dis Child* 1994; 71: F61–6.
- 2 Barry PW, Ralston C. Adverse events occurring during interhospital transfer of the critically ill. *Arch Dis Child* 1994; 71: 8–11.
- 3 Beyer AJ III, Land G, Zaritsky A. Nonphysician transport of intubated pediatric patients: a system evaluation. *Crit Care Med* 1992; 20: 961–6.
- 4 Whitfield JM, Buser MK. Transport stabilization times for neonatal and pediatric patients prior to interfacility transfer. *Pediatr Emerg Care* 1993; 9: 69–71.
- 5 McCloskey K, Hackel A. *Guidelines for air and ground transport of neonatal and pediatric patients*. Elk Grove Village, IL: American Academy of Pediatrics, 1993.

Prediction of chronic lung disease (CLD)

EDITOR,—We enjoyed reading the recent article by Ryan and coauthors on the prediction of chronic neonatal lung disease (CNLD).¹ At our own unit, using a database of all babies of <2.5 kg requiring ventilation, between 1980–1990, we derived a similar type of score using independent variables including sex, duration of exposure to FiO_2 of >0.6, and duration of exposure to a peak inspiratory pressure >25 cm H_2O .² We validated our own score by dividing the study population into a training set used to derive the score, and a test set for evaluation of sensitivity and specificity. Our sensitivity of 65% and specificity of 88% at a cutoff of $p \geq 0.50$ are lower than those of Ryan *et al* (73% and 93%, respectively).

As early intervention such as steroid treatment before 12 hours³ or between 12 and 18 hours⁴ may reduce the incidence and severity of CNLD, a predictive test that can be

calculated soon after birth is required. Unfortunately, neither our score nor that of Ryan *et al* are useful in this regard, as our score could not be calculated before the fifth day of life, and Ryan's score cannot be calculated till the seventh day.

The OSECT study (Open Study of Early Corticosteroid Treatment) is recruiting very preterm infants who have severe respiratory distress within the first 72 hours of life and it should demonstrate the value or otherwise of early treatment with systemic or inhaled steroids. It is hoped that this study will also provide further data for early prediction of CNLD. Anyone interested in further details of this trial could contact the authors at the address below.

J D CORCORAN
H L HALLIDAY
Department of Child Health,
Institute of Clinical Science,
The Queen's University of Belfast,
Grosvenor Road,
Belfast BT12 6BF

- 1 Ryan SW, Wild NJ, Arthur RJ, Shaw BNJ. Prediction of chronic lung disease in very low birthweight neonates using clinical and radiological variables. *Arch Dis Child* 1994; 71: F36–9.
- 2 Corcoran JD, Patterson CC, Thomas PS, Halliday HL. Reduction in the risk of bronchopulmonary dysplasia from 1980–1990. Results of a multivariate logistic regression analysis. *Eur J Pediatr* 1993; 152: 677–81.
- 3 Yeh TF, Torre AR, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. *J Pediatr* 1990; 117: 273–82.
- 4 Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. *Pediatr Res* 1994; 36: 122–8.